Chapter 5 Gastrointestinal Involvement in Systemic Sclerosis

Handbook of Systemic Autoimmune Diseases

Volumn 8, Issue , 2008, Pages 51-61

  Khanna, Dinesh ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 67649666497     PISSN: 15715078     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1571-5078(07)00005-0     Document Type: Review

References (46)

1. Attar A., Flourie B., Rambaud J.C., Franchisseur C., Ruszniewski P., and Bouhnik Y. Antibiotic efficacy in small intestinal bacterial overgrowth-related chronic diarrhea: a crossover, randomized trial. Gastroenterology 117 4 (1999) 794-797
2. Calamia K.T., Scolapio J.S., and Viggiano T.R. Endoscopic YAG laser treatment of watermelon stomach (gastric antral vascular ectasia) in patients with systemic sclerosis. Clin. Exp. Rheumatol. 18 5 (2000) 605-608
3. Chang J.T., and Katzka D.A. Gastroesophageal reflux disease, Barrett esophagus, and esophageal adenocarcinoma. Arch. Intern. Med. 164 14 (2004) 1482-1488
4. Clements P.J., Becvar R., Drosos A.A., Ghattas L., and Gabrielli A. Assessment of gastrointestinal involvement. Clin. Exp. Rheumatol. 21 3 Suppl. 29 (2003) S15-S18
5. Clements P.J., Kadell B., Ippoliti A., and Ross M. Esophageal motility in progressive systemic sclerosis (PSS). Comparison of cine-radiographic and manometric evaluation. Dig. Dis. Sci. 24 8 (1979) 639-644
6. Corazza G.R., Menozzi M.G., Strocchi A., Rasciti L., Vaira D., Lecchini R., et al. The diagnosis of small bowel bacterial overgrowth. Reliability of jejunal culture and inadequacy of breath hydrogen testing. Gastroenterology 98 2 (1990) 302-309
7. Di Stefano M., Veneto G., Malservisi S., and Corazza G.R. Small intestine bacterial overgrowth and metabolic bone disease. Dig. Dis. Sci. 46 5 (2001) 1077-1082
8. Duchini A., and Sessoms S.L. Gastrointestinal hemorrhage in patients with systemic sclerosis and CREST syndrome. Am. J. Gastroenterol. 93 9 (1998) 1453-1456
9. Eaker E.Y., Kuldau J.G., Verne G.N., Ross S.O., and Sallustio J.E. Myenteric neuronal antibodies in scleroderma: passive transfer evokes alterations in intestinal myoelectric activity in a rat model. J. Lab. Clin. Med. 133 6 (1999) 551-556
10. Elkayam O., Oumanski M., Yaron M., and Caspi D. Watermelon stomach following and preceding systemic sclerosis. Semin. Arthritis Rheum. 30 2 (2000) 127-131
11. Gostout C.J., Viggiano T.R., Ahlquist D.A., Wang K.K., Larson M.V., and Balm R. The clinical and endoscopic spectrum of the watermelon stomach. J. Clin. Gastroenterol. 15 3 (1992) 256-263
12. Hamel-Roy J., Devroede G., Arhan P., Tetreault L., Duranceau A., and Menard H.A. Comparative esophageal and anorectal motility in scleroderma. Gastroenterology 88 1 Pt 1 (1985) 1-7
13. Hendel L., Hage E., Hendel J., and Stentoft P. Omeprazole in the long-term treatment of severe gastro-oesophageal reflux disease in patients with systemic sclerosis. Aliment. Pharmacol. Ther. 6 5 (1992) 565-577
14. Hendel L., Svejgaard E., Walsoe I., Kieffer M., and Stenderup A. Esophageal candidosis in progressive systemic sclerosis: occurrence, significance, and treatment with fluconazole. Scand. J. Gastroenterol. 23 10 (1988) 1182-1186
15. Hetzer F.H., Hahnloser D., Clavien P.A., and Demartines N. Quality of life and morbidity after permanent sacral nerve stimulation for fecal incontinence. Arch. Surg. 142 1 (2007) 8-13
16. Howe S., Eaker E.Y., Sallustio J.E., Peebles C., Tan E.M., and Williams Jr. R.C. Antimyenteric neuronal antibodies in scleroderma. J. Clin. Invest. 94 2 (1994) 761-770
17. Jaovisidha K., Csuka M.E., Almagro U.A., and Soergel K.H. Severe gastrointestinal involvement in systemic sclerosis: report of five cases and review of the literature. Semin. Arthritis Rheum. 34 4 (2005) 689-702
18. Kenefick N.J., Vaizey C.J., Nicholls R.J., Cohen R., and Kamm M.A. Sacral nerve stimulation for faecal incontinence due to systemic sclerosis. Gut. 51 6 (2002) 881-883
19. Khanna, D., Furst, D.E. 2007. Digestive System (Gut, Gastro-intestinal) Involvement in Scleroderma. Accessed April 2007 at http://www.scleroderma.org/medical/gastro_articles/khanna_furst_2004_4.shtm. Scleroderma Voice 4. 2004.
20. Khanna D., Hays R.D., Park G.S., Braun-Moscovici Y., Mayes M.D., McNearney T.A., et al. Development of the Scleroderma Gastrointestinal Tract 1.0 (SSc-GIT 1.0) Quality of Life Instrument-Preliminary Report. Arthritis Rheum. 57 7 (2007) 1280-1286
21. Lock G., Pfeifer M., Straub R.H., Zeuner M., Lang B., Scholmerich J., et al. Association of esophageal dysfunction and pulmonary function impairment in systemic sclerosis. Am. J. Gastroenterol. 93 3 (1998) 341-345
22. Marie I., Dominique S., Levesque H., Ducrotte P., Denis P., Hellot M.F., et al. Esophageal involvement and pulmonary manifestations in systemic sclerosis. Arthritis Rheum. 45 4 (2001) 346-354
23. Marie I., Ducrotte P., Denis P., Hellot M.F., and Levesque H. Outcome of small-bowel motor impairment in systemic sclerosis--a prospective manometric 5-yr follow-up. Rheumatology (Oxford) 46 1 (2007) 150-153
24. Marie I., Levesque H., Ducrotte P., Denis P., Hellot M.F., Benichou J., et al. Gastric involvement in systemic sclerosis: a prospective study. Am. J. Gastroenterol. 96 1 (2001) 77-83
25. Massone C., Milone L., Parodi A., Pandolfo N., and Rebora A. Anorectal involvement is frequent in limited systemic sclerosis. Acta Derm. Venereol. 82 6 (2002) 446-448
26. Nietert P.J., Mitchell H.C., Bolster M.B., Curran M.Y., Tilley B.C., and Silver R.M. Correlates of depression, including overall and gastrointestinal functional status, among patients with systemic sclerosis. J. Rheumatol. 32 1 (2005) 51-57
27. Perlemuter G., Cacoub P., Chaussade S., Wechsler B., Couturier D., and Piette J.C. Octreotide treatment of chronic intestinal pseudoobstruction secondary to connective tissue diseases. Arthritis Rheum. 42 7 (1999) 1545-1549
28. Recht M.P., Levine M.S., Katzka D.A., Reynolds J.C., and Saul S.H. Barrett's esophagus in scleroderma: increased prevalence and radiographic findings. Gastrointest. Radiol. 13 1 (1988) 1-5
29. Romagnuolo J., Schiller D., and Bailey R.J. Using breath tests wisely in a gastroenterology practice: an evidence-based review of indications and pitfalls in interpretation. Am. J. Gastroenterol. 97 5 (2002) 1113-1126
30. Sallam H., McNearney T.A., and Chen J.D. Systematic review: pathophysiology and management of gastrointestinal dysmotility in systemic sclerosis (scleroderma). Aliment. Pharmacol. Ther. 23 6 (2006) 691-712
31. Sallam H., McNearney T.A., Doshi D., and Chen J.D. Transcutaneous electrical nerve stimulation (TENS) improves upper GI symptoms and balances the sympathovagal activity in scleroderma patients. Dig. Dis. Sci. 52 5 (2007) 1329-1337
32. Sampliner R.E. Updated guidelines for the diagnosis, surveillance, and therapy of Barrett's esophagus. Am. J. Gastroenterol. 97 8 (2002) 1888-1895
33. Sebastian S., McLoughlin R., Qasim A., O'Morain C.A., and Buckley M.J. Endoscopic argon plasma coagulation for the treatment of gastric antral vascular ectasia (watermelon stomach): long-term results. Dig. Liver Dis. 36 3 (2004) 212-217
34. Sebastian S., O'Morain C.A., and Buckley M.J. Review article: current therapeutic options for gastric antral vascular ectasia. Aliment. Pharmacol. Ther. 18 2 (2003) 157-165
35. Shaheen N., and Ransohoff D.F. Gastroesophageal reflux, Barrett esophagus, and esophageal cancer: scientific review. JAMA 287 15 (2002) 1972-1981
36. Sherman V., Klassen D.R., Feldman L.S., Jabbari M., Marcus V., and Fried G.M. Laparoscopic antrectomy: a novel approach to treating watermelon stomach. J. Am. Coll. Surg. 197 5 (2003) 864-867
37. Sjogren R.W. Gastrointestinal motility disorders in scleroderma. Arthritis Rheum. 37 9 (1994) 1265-1282
38. Sjogren R.W. Gastrointestinal features of scleroderma. Curr. Opin. Rheumatol. 8 6 (1996) 569-575
39. Soudah H.C., Hasler W.L., and Owyang C. Effect of octreotide on intestinal motility and bacterial overgrowth in scleroderma. N. Engl. J. Med. 325 21 (1991) 1461-1467
40. Stotzer P.O., Johansson C., Mellstrom D., Lindstedt G., and Kilander A.F. Bone mineral density in patients with small intestinal bacterial overgrowth. Hepatogastroenterology 50 53 (2003) 1415-1418
41. Troshinsky M.B., Kane G.C., Varga J., Cater J.R., Fish J.E., Jimenez S.A., et al. Pulmonary function and gastroesophageal reflux in systemic sclerosis. Ann. Intern. Med. 121 1 (1994) 6-10
42. Verne G.N., Eaker E.Y., Hardy E., and Sninsky C.A. Effect of octreotide and erythromycin on idiopathic and scleroderma-associated intestinal pseudoobstruction. Dig. Dis. Sci. 40 9 (1995) 1892-1901
43. Wald A. Is chronic use of stimulant laxatives harmful to the colon?. J. Clin. Gastroenterol. 36 5 (2003) 386-389
44. Weinstein W., and Kadell B.M. The gastrointestinal involvement in systemic sclerosis. In: Clements P.J., and Furst D.E. (Eds). Systemic Sclerosis (2004), Lippincott Williams and Wilkins, Philadelphia 293-308
45. Wipff J., Allanore Y., Soussi F., Terris B., Abitbol V., Raymond J., et al. Prevalence of Barrett's esophagus in systemic sclerosis. Arthritis Rheum. 52 9 (2005) 2882-2888
46. Zhang J., and Chen J.D. Systematic review: applications and future of gastric electrical stimulation. Aliment. Pharmacol. Ther. 24 7 (2006) 991-1002